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 The thesis is intended to contribute fundamentally to the research effort of 
the Supply Chain 2020 project (SC 2020).  The SC2020 research initiative is structured 
toward providing insight into major research questions about the future of supply chain 
excellence.  The SC 2020 project will attempt to accurately and concisely describe the 
structure and nature of how supply chains will have probably evolved by the year 2020.  
In order to examine the nature of a specific industry within the scope of the SC 2020 
project, the author chose to examine pharmaceutical supply chains.  To further identify 
critical success factors, the author chose to examine Novartis AG, a Switzerland based 
top-10 pharmaceutical company.  The following content will provide valuable insight into 
the current structure of pharmaceutical supply chains including the key components that 
make certain supply chains “excellent.”   
 The pharmaceutical industry generally includes companies who focus on the 
research, development, production, and sale of drug substances and compounds for 
medical use.  These companies require industry specific supply chain practices geared 
toward compensating for the myriad of idiosyncrasies in the industry including unusually 
high markups, elevated R&D costs, increased governmental regulation, and substantial 
lead and cycle times.  A number of trends are contributing to variations within the 
industry and are compounding the complexity of these pharmaceutical supply chains.  
Some current industry trends include: decreasing R&D efficiency; increasing regulatory 
and pricing pressures; increasing generic competition; shifting production methods from 
chemical to biopharmaceutical or genetic processes.  Current regulatory policy in the US 
is conducive to generic producers and offers exclusivity periods for newcomers in the 
market.  Increasing pricing pressures amongst a consolidated supplier base and SKU 
proliferation are creating a need for leaner and more efficient supply chain processes.  
The industry is also experiencing more frequent stock outs in spite of record high 
inventories; this complexity is compounded by products with cycle times that often 
exceed 12 months and lead times in excess of 10 years.  
Novartis is a geographically diverse company that was created through a history 
of mergers and acquisitions.  The company has product offerings in consumer health, 
over-the-counter (OTC), generic, and prescription pharmaceutical products.  Within the 
pharmaceutical products division, the company focuses its R&D efforts around key 
therapeutic categories surrounding the treatment of chronic illnesses.  Amongst its 
therapeutic categories, Novartis considers itself a market leader in transplantation 
products.  Novartis maintains a robust pipeline of drug compounds in development; these 
compounds determine the future success of Novartis.  In addition to successful R&D, 
Novartis owes its success to a sound strategy with a complimentary operating model, 
sound objectives with appropriate metrics, and aligned practices and processes. 
Strategy 
 The pharmaceutical division focuses its core business strategy around adding new 
profitable and patent protected products to its broad portfolio of treatments for chronic 
illnesses; Novartis utilizes a broad product portfolio, including generic products, to 
reduce reliance on blockbuster drugs and maintain market share after patent expirations.  
Generics products also allow Novartis to capture market share for competitors’ off-patent 
products.  Novartis chooses to focus R&D efforts primarily on chronic illness products 
since these products are administered on a perpetual basis and are not subject to material 
variations in demand.  Novartis also strives for global market reach and operates in over 
140 countries worldwide.  It maintains a broad and geographically diverse asset base that 
allows Novartis to serve extremely diverse markets and promote business continuity.   
Operating Model 
Novartis chooses an operating model that supports its strategy of creating a 
diversified product portfolio by vertically integrating its supply chain.  Vertical 
integration allows Novartis to retain more profits and increase control over production.  
The added control offers Novartis the ability to optimize tax benefits by manufacturing 
products in low tax regions.  Novartis also is able to increase asset utilization through 
resource sharing.  Unfortunately, vertical integration also increases complexity.  The 
increased complexity is managed through a focused brand pipeline management structure 
where each key product is evaluated separately in the production process.  The company 
operates production and sales facilities across a very broad geographical base.  This broad 
base allows Novartis to employ customized sales practices and meet regulatory and 
language in each country that it services.  Novartis also receives financial benefits from 
the broad array of facility locations. Taxation structures vary between countries and 
regions; Novartis is able to produce products in the regions which allow the company to 
retain the highest amount of profit. The Novartis operating model is designed to 
support the high degree of complexity that occurs with a broad portfolio and vertical 
integration.  The company maintains a globally and centrally managed approach to certain 
aspects of its supply chain.  Throughout the production process, key products which are 
managed at a brand pipeline level remain visible to global management, while local 
facility decisions are managed locally.  Novartis employs a matrix organization that 
allows both functional and process efficiency.  
The Novartis Supply Chain Management (SCM) group places a focused emphasis 
on operational objectives to support the operating model.  The company tries to reduce 
both the cycle and lead times for the production.  Novartis is pursuing an initiative 
entitled “Launch in 1000 days” which is designed to limit the time it takes to bring a new 
product to market. In the past, it often took over 5 years to bring new product launches to 
market.  One of the key goals in place for the SCM group is centered on maximizing 
production capacity and asset utilization.  The centralized operating model allows 
Novartis to efficiently allocate capacity amongst product production campaigns.  The 
brand pipeline management approach achieves superior information flows which lead to 
better physical flows of products.  This approach also allows Novartis to maintain end-to-
end visibility of products.  The global SCM group tries to achieve better traceability and 
control over material flows and asset utilization.  Novartis SCM also tries to achieve 
global inventory reduction throughout the supply chain by utilizing benchmarking 
techniques to monitor overall inventory levels on both an aggregate and brand pipeline 
level.  
Operational Objectives 
In an effort to facilitate shorter lead and cycle times, Novartis employs a parallel 
approach to the development and production of new products.  While products are still in 
clinical development, Novartis removes boundaries and separation between their clinical 
and production supply chains.  This allows better sharing of knowledge and information 
during the development process.  Key aspects of the clinical production process are 
shared with production engineers.  The early knowledge transfer allows Novartis to begin 
the certification process for their production techniques in sync with the product’s 
regulatory approval.   
Complimentary Processes 
Turntable 
Novartis utilizes a supply chain turntable to exercise control over production and 
to better manage the high degree of complexity resulting from a broad product portfolio, 
vertical integration, and broad geographical asset base.  The turntable is located in Basel 
Switzerland, and often manages over 10,000 simultaneous open orders with over 50,000 
order lines per year (Novartis Interview 2005).  Even with over 20,000 inter-company 
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shipments annually, Novartis spends less than $20 million annually on transportation.  
The turntable allows Novartis to centrally manage their vertically integrated supply chain 
and improve visibility and tracking of products and materials through the production 
process.  Additionally, in support of the company’s tax optimization strategy, the 
turntable serves as a financial hub for all inter-company transactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collaborative Forecasting 
Novartis employs a well developed collaborative process for sales forecasting.  
Each country or region specific sales organization develops its own sales forecast which 
is then passed up to the global sales and planning group.  The supply chain planning 
process begins with a sales forecast.  The forecasts will include information about the 
expected volume of sales as well as the projected financial impact of those sales.  The 
sales staff must also produce accurate accounting of their assumptions about the forecast 
Figure 1: Operating Model (Novartis Global Supply Chain Management Presentation 
- Induction program to newcomers in the organisation 2005) 
Figure 2: Tu ntable and KPI I ustration (Novartis Global Supply Ch in 
Management Presentation – Turntable Operations Basel 2005) 
including explanations as to how and why each value was determined.  The forecasting 
team must take into consideration each particular Brand Strategy, Historical Sales 
information, Market Intelligence, and other pertinent inputs to the forecasting process.  
Through better sharing of assumptions in the sales forecasting process, Novartis is able to 
achieve lower safety stock and inventory through the supply chain. 
Scheduling and Planning 
To achieve high levels of asset utilization Novartis uses well founded planning 
and scheduling methods.  Their broad product portfolio combined with a need for asset 
sharing requires more frequent setups and changeovers of production equipment.  This 
added complexity requires Novartis to undergo a robust and formalized scheduling and 
planning process. The production planning process must be composed of both centralized 
and distributed decision making activities simultaneously.  The brand pipeline 
management approach helps facilitate this process and reduce overlap in planning efforts.  
Novartis also utilizes their accurate sales forecasts to assist in producing better facility 
production plans.  Novartis tries to operate approximately two production campaigns per 
product per year in order to keep changeovers and setup costs to a minimum.  Improper 
planning could result in lowered efficiency throughout the supply chain. 
Conclusion 
Overall, Novartis employs a focused business strategy which forgoes 
opportunities in certain markets in order to focus on its core competency of producing 
profitable, chronic illness products.  The operating model supports this strategy through 
centralized management of production and complexity.  Novartis focuses on improving 
operational efficiency through the use of customized processes and KPIs.  Novartis also 
employs supporting processes which increase accuracy and profitability throughout the 
supply chain.  This supporting hierarchical supply chain structure certainly exhibits the 
traits of an excellent supply chain.       
 
 
   
 
 
